Overview

Sunitinib is a multi-target tyrosine-kinase inhibitor whose value to B2B buyers lies in one molecule serving several tumor types, which simplifies consolidated procurement. The sourcing premise is that a single SKU spanning renal cell carcinoma, gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, and thyroid cancer reduces inventory fragmentation. The 12.5 mg tablet from Beacon, supplied in 28-tablet packs, is the foundational strength in a staggered dosing range. For distributors, that shared demand means forecasting one product can serve several oncology departments, improving capital efficiency.

How It Works

Sunitinib inhibits multiple receptor tyrosine kinases including VEGFR, PDGFR, KIT, and FLT3, choking the angiogenic and proliferative signals that drive tumor growth. Blocking VEGFR and PDGFR starves vessels that feed the tumor, while KIT inhibition addresses GIST driven by that receptor. This multi-kinase breadth is exactly why one product covers indications that single-target drugs cannot. By hitting both angiogenic and receptor-driven signals, the molecule addresses tumor growth and its blood supply at the same time, a dual action few single-target drugs match.

Indications

Sunitinib is used in advanced renal cell carcinoma, imatinib-resistant or intolerant GIST, progressive pancreatic neuroendocrine tumors, and certain thyroid and thymic tumors. Dose varies by indication, from 50 mg four-weeks-on/two-weeks-off in RCC to lower continuous schedules elsewhere. Procurement should map pack sizes to the prescribed regimen. Adjuvant RCC use in higher-risk postoperative patients further extends the shared SKU across both metastatic and earlier-stage services.

Dosage & Administration

The oral dose is individualized; the 12.5 mg tablet enables fine titration and the 28-tablet pack supports monthly cycles at lower strengths. Higher regimens use 25 mg and 50 mg tablets within the same family. Treatment continues while benefit and tolerance are maintained under periodic imaging review by the treating team.

Storage & Sourcing

Store Sunitinib below 30°C in the original blister, protected from moisture; no cold-chain is needed. For export, consolidated batch documentation, expiry tracking, and serialization support audit-ready supply. Multi-indication demand lets distributors pool stock and improve fill rates across regions. Absence of cold-chain need lets regional hubs stock deeper safety inventory without refrigerated capacity constraints.

FAQ

Q: Which indications share the same Sunitinib supply chain? A: Renal cell carcinoma, GIST, pancreatic neuroendocrine tumor, and selected thyroid tumors all draw from one product family, enabling unified inventory.

Q: What batch documentation supports Sunitinib export sourcing? A: Certificate of Analysis, GMP statements, expiry, and serialization per pack let importers verify authenticity and satisfy customs review.

Q: How are cold-chain breaks avoided during Sunitinib transit? A: Room-temperature stability removes refrigeration dependence, so insulated packaging and desiccant control moisture rather than active cooling.